Vyznova is under clinical development by Aurion Biotechnologies and currently in Phase II for Corneal Edema. According to GlobalData, Phase II drugs for Corneal Edema does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vyznova LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vyznova overview
Vyznova a human corneal endothelial cell therapy. It is formulated as solution for intracameral route of administration. Vyznova is indicated for the treatment of bullous keratopathy of the cornea.
AE-101 is under development for the treatment of corneal endothelial dysfunction corneal edema secondary to endothelial dysfunction. The drug candidate is administered through intracameral route. The drug candidate combination cell therapy product (biologic/drug) comprised of neltependocel (allogeneic human corneal endothelial cells (CECs]) and Y-27632 (an inhibitor of Rho-associated, coiled-coil containing protein kinase [ROCK]).
Aurion Biotechnologies overview
Aurion Biotechnologies is a biotech company that specialized in corneal endothelial disease cell treatment. It is headquartered in Boston, Massachusetts, United States.
For a complete picture of Vyznova’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
